Shares of Teva Pharmaceutical Industries Limited (TEVA) are rising more than 13% Wednesday morning after reporting second quarter results above analyst' view. The company also raised its full-year revenue outlook.
Excluding one-time items, the company reported earnings of $629 million or $0.56 per share, that beat the average estimate of analysts polled by Thomson-Reuters of $0.52 per share.
Net loss in the second quarter was $863 million or $0.77 per share, wider than $232 million or $0.21 per share last year, mainly due to lower tax benefit.
Revenues in the quarter were $3.878 billion, an increase of 2% from the previous-year quarter. The consensus estimate was for $3.71 billion.
For the full year, Teva now expects revenue in the range of $15.0 billion-$15.4 billion, up from the previous outlook of $14.8 billion-$15.4 billion.
Adjusted EPS for the year is expected between $2.25 and $2.55.
Analysts expect the company to report earnings of $2.27 per share on revenue of $15.02 billion for the period.
TEVA is at $9.40 currently. It has traded in the range of $7.09 - $11.45 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.